Johnson & Johnson Aktie News

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call...

The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products receiving an award under the program to 16 this year.

The Social Security Administration announced in October that beneficiaries will receive a 2.8% cost-of-living adjustment (COLA) in 2026, following a 2.5% increase in 2025.

LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury on Friday delivered a $40 million verdict against Johnson & Johnson. The trial involved two women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and her husband, Dr. Albert Schultz, totals $40 million in compensatory damages...

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.

LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury today delivered a $40 million verdict against Johnson & Johnson. The trial featured two California women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and her husband, Dr. Albert Schultz, totals $40 million in compensatory ...

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa. , Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA...